Patents by Inventor David R. Anderson

David R. Anderson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220232816
    Abstract: A predictive map is obtained by an agricultural material application system. The predictive map maps predictive weed values at different geographic locations in a field. A geographic position sensor detects a geographic locations of an agricultural material application machine at the field. A control system generates a control signal to control the agricultural material application machine based on the geographic locations of the agricultural material application machine and the predictive map.
    Type: Application
    Filed: April 8, 2022
    Publication date: July 28, 2022
    Inventors: Nathan R. VANDIKE, Bhanu Kiran Reddy PALLA, Federico PARDINA-MALBRAN, David A. Hanson, Andrea M. Agarwal, Noel W. Anderson
  • Patent number: 11379777
    Abstract: Techniques are described herein that are capable of estimating a result of configuration change(s) in an enterprise. Enterprise information regarding a designated enterprise is gathered. The enterprise information is combined with anonymized information that is received from multiple enterprises to provide combined information. An actual impact of configuration changes in at least one enterprise (e.g., with regard to a first subset of the machines therein) is determined and/or a predictive impact of the configuration change(s) in at least one enterprise (e.g., with regard to a second subset of machines therein) is inferred. An estimate of a net financial result of implementing the configuration change(s) (e.g., with regard to the second subset of the machines) in the designated enterprise is generated based at least in part on the actual impact and/or the predictive impact.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: July 5, 2022
    Assignee: Microsoft Technology Licensing, LLC
    Inventors: Marc Shepard, Brad R. Anderson, David C. James, Brett Damon Alan Flegg
  • Publication number: 20220153755
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Application
    Filed: January 27, 2022
    Publication date: May 19, 2022
    Inventors: David R. Anderson, Robert Volkmann, Frank Menniti, Christopher Fanger, Yuelian Xu
  • Patent number: 11274107
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 15, 2022
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank Menniti, Christopher Fanger, Yuelian Xu
  • Publication number: 20220047600
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Application
    Filed: August 27, 2021
    Publication date: February 17, 2022
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Patent number: 11236104
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: February 1, 2022
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Publication number: 20220016117
    Abstract: Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Application
    Filed: February 26, 2021
    Publication date: January 20, 2022
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Publication number: 20210403474
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: February 12, 2021
    Publication date: December 30, 2021
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • Patent number: 11116749
    Abstract: Compounds that selectively negatively modulate NMDA receptors containing an NR1/NR2B subunit, pharmaceutical compositions comprising the compounds, and methods of treating a disease using the compounds are disclosed.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: September 14, 2021
    Assignee: CADENT THERAPEUTICS, INC
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
  • Publication number: 20210107916
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
    Type: Application
    Filed: January 31, 2020
    Publication date: April 15, 2021
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Patent number: 10973825
    Abstract: Disclosed herein, in part, are methods of treating neurological disorders, e.g., schizophrenia and major depressive disorder, comprising administering an effective amount of a disclosed heterocyclic compound. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 13, 2021
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Publication number: 20200369610
    Abstract: The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R1, R2, L1, L2, X, Y, and Y? are described therein.
    Type: Application
    Filed: August 12, 2020
    Publication date: November 26, 2020
    Applicant: CADENT THERAPEUTICS, INC.
    Inventors: David R. ANDERSON, Robert A. VOLKMANN, Frank S. MENNITI
  • Patent number: 10781174
    Abstract: The present disclosure relates to N-alkylaryl-5-oxyaryl-octadihydrocyclopent[c]pyrrole negative allosteric modulators of NR2B receptors useful in the treatment of neurological diseases having the Formula I: where R1, R2, L1, L2, X, Y, and Y? are described therein.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: September 22, 2020
    Assignee: CADENT THERAPEUTICS, INC.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti
  • Patent number: 10752633
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: August 25, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • Publication number: 20200193544
    Abstract: A relationship management apparatus, method and computer program product providing a user interface containing treatment protocol for an individual comprising: (a) a user interface electrically connected with a data storage device; (b) a server electrically connected with the user interface and the data storage device; and (c) a treatment processor electrically connected with the server, wherein the treatment processor is configured to generate an optimized treatment protocol for the individual.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 18, 2020
    Applicant: OPTUMINSIGHT, INC.
    Inventors: David R. Anderson, Jean Rawlings
  • Publication number: 20200131190
    Abstract: Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.
    Type: Application
    Filed: November 8, 2019
    Publication date: April 30, 2020
    Inventors: David R. Anderson, Robert A. Volkmann, Gregg F. Keaney, Steven C. Leiser, Sam Malekiani, Timothy Piser
  • Patent number: 10626122
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 21, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Publication number: 20200087323
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Application
    Filed: December 22, 2017
    Publication date: March 19, 2020
    Inventors: David R. Anderson, Robert A. Volkmann, Frank Menniti, Christopher Fanger, Yuelian Xu
  • Patent number: 10593001
    Abstract: A relationship management device and method providing a user interface containing treatment protocol for an individual comprising: (a) a user interface electrically connected with a data storage device; (b) a server electrically connected with the user interface and the data storage device; and (c) a treatment processor electrically connected with the server, wherein the treatment processor is configured to generate an optimized treatment protocol for the individual.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: March 17, 2020
    Assignee: OPTUMINSIGHT, INC.
    Inventors: David R. Anderson, Jean Rawlings
  • Patent number: RE48795
    Abstract: A system for controlling an electricity supply to a load comprises at least one battery for storing energy. The system also comprises a controller for determining when to switch between a first mode wherein electricity is supplied to the load from a mains electricity circuit; and a discharging mode wherein electricity is supplied from the battery to the load via the mains electricity circuit. The determining is based on information associated with the electricity supply.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: October 26, 2021
    Assignee: The Technology Partnership PLC
    Inventors: Mathew R. Palmer, Antony W. Rix, David R. Anderson, David S. Smith, Matthew C. B. Lumb